MAY 2025 | MONTHLY ISSUE

# Newsletter




UNVEILING THE LATEST UPDATES AND INSIGHTS

INSIDE THIS ISSUE:

Special Highlight | Upcoming Events | Recently Published Papers | Meeting New Members

# **Special Highlight**





### 13-16 May 2025 | ISPOR 2025 Annual Conference

Prof. Esther Chan, Prof. Shirley Li, and their team attended the ISPOR 2025 Annual Conference at the Palais des congrès de Montréal, Canada. As a premier global event for health economics and outcomes research, the conference provided an excellent opportunity to showcase their latest work, including:

- Cost-effectiveness of esketamine for treatment-resistant depression
- Global drug utilization study on WHO essential cancer medicines

The team engaged with international experts, exchanging insights on real-world data analysis, value assessment, and Al-driven health technology evaluation.



#### 17 May 2025 | ECHORA Inaugural Network Meeting at KCL

Prof. Shirley Li participated in the inaugural network meeting of the European China Health Economics and Outcomes Research Association (ECHORA) at King's College London. This landmark event marked the first official gathering of ECHORA members, establishing a new platform for Europe-China collaboration in health economics and outcomes research.





30 May - 1 June 2025

### The 13th Southern Pharmacoeconomics Forum (Guangzhou, China)

Dr. Edmund Yiu was an invited speaker to present his pilot study exploring the application of time trade-off and discrete choice experiment methods for valuing the Chinese Short Warwick-Edinburgh Mental Well-being Scale (C-SWEMWBS) in Hong Kong. The results will help identify the most appropriate health preference methodology to derive the Hong Kong public mental well-being value set for estimating Mental Well-being Adjusted Life Years (MWALYs).





30 May - 1 June 2025

### The 13th Southern Pharmacoeconomics Forum (Guangzhou, China)

Peng Kuan attended the 13th Southern Pharmacoeconomics Forum in Guangzhou as a guest speaker, where he presented research findings on the application of artificial intelligence in evaluating the safety of biological medications.





### 22 May 2025 | Big Data in Primary Care Workshop)

The Primary Healthcare Collaboratory hosted a workshop on big data integration in primary care, moderated by Prof. Eric Wan. Experts explored how data-driven approaches can transform healthcare research and outcomes.



#### 24 May | Grant Writing Seminar

**Prof. Eric Wan moderated** an insightful seminar where Prof. Chris Leung and Prof. Doris Yu shared expert strategies for developing competitive proposals for the Strategic Topics Grant. Hosted by the Primary Comprehensive Healthcare Collaboratory, this event provided valuable guidance for researchers seeking funding success.

### **Upcoming Events**



Prof. Celine Chui will be speaking at the 33rd Annual Scientific Congress of the Hong Kong College of Cardiology!

• Date: June 7, 2025 Time: 11:00 AM - 12:30 PM

Location: Hong Kong Convention and Exhibition Centre (HKCEC)

Don't miss this opportunity to hear from Prof. Chui! Register HERE!

### **Recently Published Papers**

**Kyung Jin Lee, Esther Chan The Lancet Regional Health - Western Pacific** 

A decade of Benzodiazepine and Z-drug use in Hong Kong: a longitudinal study

See publication here

Shirley Li
The Lancet Rheumatology in conversation

See publication here

### Zhuoran Hu, Eric Wan Hypertension Research

Indirect effect of the COVID-19 pandemic on cardiovascular diseases incidence, mortality, and healthcare use among patients with hypertension but without SARS-CoV-2 infection in Hong Kong: an interrupted time series analysis

See publication here



Articles

A decade of Benzodiazepine and Z-drug use in Hong Kong: a longitudinal study

#### The Lancet Regional Health in conversation with

## Xue Li on access to biologics in the Asia-Pacific region



#### Hypertension Research

Article

Special Issue: Current evidence and perspectives for hypertension management in Asia
Published: 23 May 2025

Indirect effect of the COVID-19 pandemic on cardiovascular diseases incidence, mortality, and healthcare use among patients with hypertension but without SARS-CoV-2 infection in Hong Kong: an interrupted time series analysis

Zhuoran Hu, Yuk Kam Yau, Jianchao Quan, Karen Ann Grépin, Ivy Lynn Mak, Gary
Kui Kai Lau, Ian Chi Kei Wong, David Vai Kiong Chao, Welchie Wai Kit Ko, Chak Sing
Lau, Cindy Lo Kuen Lam & Eric Yuk Fai Wan 

✓



### **Meeting New Members**

A very warm welcome from the whole CSMPR team to our new members!

66 Hello everyone! I'm Roni, a new Research Assistant from Prof. Esther Chan's team. My research interests lie in pharmacoepidemiology, mainly about the safety and effectiveness of medicines using the big data. I enjoy travelling and trying the various cuisines. I aspire to become a PhD student and contribute to human health in the future. So glad to be part of the team! ??



RONI ZHENG



WEIQI GAO

Hello everyone! I'm Weiqi, a new Research Assistant in Prof. Esther Chan's team. My research interests focus on medical AI, multimodal deep learning, & clinical risk prediction using electronic health records. I'm passionate about developing interpretable AI systems that support real-world healthcare applications. Outside of research, I enjoy badminton and photography. I'm very excited to be part of this interdisciplinary team and look forward to collaborating with all of you.

#### **About CSMPR**

Centre for Safe Medication Practice and Research (CSMPR) was established in 2012 to foster research and development in medication safety in collaboration with local and international partners.

The mission of the CSMPR is to improve the health and quality of life of patients through interdisciplinary collaborative research that addresses questions central to medication safety. We focus on delivering innovative results that optimise the safe and effective use of medications. Combining expertise from the University of Hong Kong (HKU) and collaborative partners around the globe, the CSMPR provides a world-renowned platform for the training of health care professionals, patients and the general public on the safe and effective use of medications.

Our aim is to deliver high quality research with results relevant and applicable to health in real world settings, thus optimising and promoting the safe and effective use of medicine in Asia and beyond.

